Market Access strategies for a drug are that set of levers that pull and promote market access, adoption, and recognition of the drug's value. This process shifts the focus from the prescriber to a variety of stakeholders.
There are different kinds of levers than can be used to drive a successful market access strategy: from clinical and epidemiological evidence to pharmaco-economics and regulations in place.
For the proper management of a pharmaceutical product in the market, it is now essential to analyze and know its access strategies: regional approach models, hospital tenders, purchasing procedures, operational tools, and finally, stakeholders.
Market Access has an integrating role that expands over the product's life: from the first clinical trials to patent expiration. Despite this, it plays the most critical role in the clinical development phase to support the manufacturer in the reimbursability goals of the new drug.
The training sessions in Market Access cover all topics of interest: targeted notions of market access for healthcare products, positioning strategies, "payers," different scenarios, etc.
The courses are primarily aimed at those working in Market Access departments but also open to those from areas such as Marketing, Institutional Affairs and Commercial Affairs.
The courses, seminars and workshops on Market Access will enhance all the needed skills to work in this specific field.
Pharmaceutical market access: what it is and why it matters
Pharmaceutical market access is the set of activities that gets a drug from the lab to the patient, covering price, reimbursement and acceptance by the healthcare system. It goes beyond setting a price: it includes clinical evidence, pharmacoeconomics, the regulatory framework and ongoing dialogue with payers, hospitals and institutions.
Anyone working in this field needs to understand regional access models, hospital tenders, procurement procedures and the operational tools that shape the relationship between a pharmaceutical company and the healthcare system. Market access runs across the entire life of a product, from early clinical studies to patent expiry, but it carries the most weight during development, when the reimbursement dossier gets built.
Market access strategy pharmaceutical: the levers that matter
A pharmaceutical market access strategy rests on several levels. The first is evidence generation: clinical studies, real world evidence data and Health Technology Assessment (HTA) evaluations that demonstrate a drug's therapeutic and economic value. The second is regulatory: the new European HTA regulation, with its Joint Scientific Consultation (JSC) and Joint Clinical Assessment (JCA) processes, is changing how clinical evaluations are run at EU level and adopted by individual countries.
The third level is negotiation: price, reimbursement, launch plans and dealings with national and regional pricing bodies. An Access Lead needs to read all three levels together, not as separate compartments.
Market access pharma online course: LS Academy's training path
LS Academy's courses in this area cover the full market access cycle, not just the final negotiation stage. The path starts with searching and appraising the medical literature, a necessary step for building a solid dossier, and moves through a critical reading of the new European HTA regulation and its impact on JSC, JCA and national decision-making.
A market access pharma online course from LS Academy also covers the operational side: how to build an access plan, how to negotiate price with national pricing authorities, how to engage the different healthcare stakeholders, from hospital payers to regional institutions. The courses are designed for professionals already working in Market Access departments, as well as for those coming from marketing, public affairs or commercial roles who need to understand how the field works.
Market access medical device: a related but distinct field
Market access for medical devices follows a partly different logic than pharmaceuticals: the regulatory framework changes (Regulation (EU) 2017/745, MDR), so do the reimbursement channels and the stakeholders involved in decision-making. LS Academy runs a dedicated path for this area, built for professionals working in medical device companies who need to design an access strategy consistent with the rules of this sector.
Frequently asked questions
What is pharmaceutical market access?
It's the set of clinical, economic and regulatory activities that allow a drug to gain reimbursement and reach patients through the healthcare system. It includes evidence generation, HTA assessment and price and reimbursement negotiation.
Who is a pharmaceutical market access course for?
For professionals working in Market Access departments at pharmaceutical companies, as well as those in marketing, public affairs and commercial functions who need to understand how pharmaceutical market access works.
What's the difference between pharmaceutical market access and medical device market access?
Pharmaceutical market access follows reimbursement and HTA rules that apply to drugs. Medical device market access is based on a different regulatory framework, Regulation (EU) 2017/745, and on reimbursement channels specific to that sector.
What changes with the new European HTA regulation?
It introduces shared processes at EU level, the Joint Scientific Consultation and the Joint Clinical Assessment, which standardise comparative clinical evaluations across member states and then feed into national pricing and reimbursement decisions.